Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10911232 | Lung Cancer | 2013 | 7 Pages |
Abstract
This regimen achieves substantial LTS. Interestingly, adenocarcinomas, older patients, unfavorable comorbidity scores, higher BMI and light smokers demonstrate poor long-term outcome even with aggressive trimodality. This dataset defines the rationale for our ongoing randomized trial with surgery after induction therapy in IIIA(N2)/selected IIIB (ESPATÃ).
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Wilfried Ernst Erich Eberhardt, Thomas Christoph Gauler, Cecile LePechoux, Georgios Stamatis, Stephan Bildat, Thomas Krbek, Stefan Welter, Dominique Grunenwald, Berthold Fischer, Hepp de los Rios Rodrigo, Dirk Theegarten, Thierry Le Chevalier,